Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 18;6(2):521–527. doi: 10.1182/bloodadvances.2021006139

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

PMC Copyright notice

Figure 1. — Treatment procedures and response in patients treated with CPX-351. (A) Timeline of treatment procedures. (B) Range and median reduction in BM cellularity and blasts after treatment with CPX-351. (C) BM biopsy findings for Patient 7 at diagnosis of AML with MDS-related changes and hyperinflammation (panels i-iii) and 1 month after a single cycle of CPX-351 (panel iv). (i) Hypercellular marrow with sheets of dysplastic megakaryocytes (hematoxylin and eosin [H&E] stain; original magnification ×200). (ii) Increased immature mononuclear cells, normal hematopoiesis absent (H&E stain; original magnification ×600). (iii) Reticulin fibrosis (reticulin stain; original magnification ×400). (iv) Hypocellular marrow with no dysplastic cells or fibrosis (H&E stain; original magnification ×600). FLAG, fludarabine, cytarabine, granulocyte colony-stimulating factor regimen; T-ALL, T-cell acute lymphoblastic leukemia.